The Library
Belimumab : a technological advance for systemic lupus erythematosus patients? Report of a systematic review and meta-analysis
Tools
Tools
Tools
Kandala, Ngianga-Bakwin, Connock, M., Grove, Amy L., Sutcliffe, P. (Paul), Mohiuddin, Syed, Hartley, Louise, Court, Rachel A., Cummins, E., Gordon, Caroline and Clarke, Aileen (2013) Belimumab : a technological advance for systemic lupus erythematosus patients? Report of a systematic review and meta-analysis. BMJ Open, Volume 3 (Number 7). Article number e002852. doi:10.1136/bmjopen-2013-002852 ISSN 2044-6055.
|
Text
WRAP_BMJ Open-2013-Kandala-.pdf - Published Version Available under License Creative Commons Attribution Non-commercial Share Alike. Download (1788Kb) | Preview |
Official URL: http://dx.doi.org/10.1136/bmjopen-2013-002852
Abstract
Objectives: To undertake a systematic review and meta-analysis to investigate clinical effectiveness of belimumab for patients with systemic lupus erythematosus (SLE) and antinuclear and/or anti-double-stranded DNA (dsDNA) autoantibodies.
Methods: We searched eight electronic databases and reference lists for randomised controlled trials (RCTs) of belimumab against placebo or best supportive care. Quality assessment and random effects meta-analysis were undertaken.
Design: A meta-analysis of RCTs.
Participants: 2133 SLE patients.
Primary and secondary outcome measures: SLE Responder Index (SRI) at week 52.
Results: Three double-blind placebo-controlled RCTs (L02, BLISS-52 BLISS-76) investigated 2133 SLE patients. BLISS-52 and BLISS-76 trials recruited patients with antinuclear and/or anti-dsDNA autoantibodies and demonstrated belimumab effectiveness for the SRI at week 52. Ethnicity and geographical location of participants varied considerably between BLISS trials. Although tests for statistical heterogeneity were negative, BLISS-52 results were systematically more favourable for all measured outcomes. Meta-analysis of pooled 52-week SRI BLISS results showed benefit for belimumab (OR 1.63, 95% CI 1.27 to 2.09). By week 76, the primary SRI outcome in BLISS-76 was not statistically significant (OR 1.31, 95% CI 0.919 to 1.855).
| Item Type: | Journal Article | ||||
|---|---|---|---|---|---|
| Subjects: | R Medicine > R Medicine (General) R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine R Medicine > RM Therapeutics. Pharmacology |
||||
| Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences > Population, Evidence & Technologies (PET) > Warwick Evidence Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School |
||||
| Library of Congress Subject Headings (LCSH): | Clinical trials -- Data processing, Automimmune diseases -- Treatment, Evidence-based medicine -- Great Britain, Systematic reviews (Medical research), Systemic lupus erythematosus -- Treatment, Systemic lupus erythematosus | ||||
| Journal or Publication Title: | BMJ Open | ||||
| Publisher: | BMJ | ||||
| ISSN: | 2044-6055 | ||||
| Official Date: | 2013 | ||||
| Dates: |
|
||||
| Volume: | Volume 3 | ||||
| Number: | Number 7 | ||||
| Page Range: | Article number e002852 | ||||
| DOI: | 10.1136/bmjopen-2013-002852 | ||||
| Status: | Peer Reviewed | ||||
| Publication Status: | Published | ||||
| Access rights to Published version: | Open Access (Creative Commons) | ||||
| Date of first compliant deposit: | 25 December 2015 | ||||
| Date of first compliant Open Access: | 25 December 2015 | ||||
| Funder: | National Institute for Health Research (Great Britain) (NIHR) | ||||
| Grant number: | 10/73/01 |
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
Downloads
Downloads per month over past year
